Probiotic Helminth Administration in Relapsing-remitting Multiple Sclerosis: a Phase 1 Study

Overview

Journal Mult Scler

Publisher Sage Publications

Specialty Neurology

Date 2011 Mar 5

PMID 21372112

Citations 109

Authors

J O Fleming

A Isaak

J E Lee

C C Luzzio

M D Carrithers

T D Cook

A S Field

J Boland

Z Fabry

Affiliations

Soon will be listed here.

Abstract

Background: Probiotic treatment strategy based on the hygiene hypothesis, such as administration of ova from the non-pathogenic helminth, Trichuris suis, (TSO) has proven safe and effective in autoimmune inflammatory bowel disease.

Objective: To study the safety and effects of TSO in a second autoimmune disease, multiple sclerosis (MS), we conducted the phase 1 Helminth-induced Immunomodulatory Therapy (HINT 1) study.

Methods: Five subjects with newly diagnosed, treatment-naive relapsing-remitting multiple sclerosis (RRMS) were given 2500 TSO orally every 2 weeks for 3 months in a baseline versus treatment control exploratory trial.

Results: The mean number of new gadolinium-enhancing magnetic resonance imaging (MRI) lesions (n-Gd+) fell from 6.6 at baseline to 2.0 at the end of TSO administration, and 2 months after TSO was discontinued, the mean number of n-Gd+ rose to 5.8. No significant adverse effects were observed. In preliminary immunological investigations, increases in the serum level of the cytokines IL-4 and IL-10 were noted in four of the five subjects.

Conclusion: TSO was well tolerated in the first human study of this novel probiotic in RRMS, and favorable trends were observed in exploratory MRI and immunological assessments. Further investigations will be required to fully explore the safety, effects, and mechanism of action of this immunomodulatory treatment.

Citing Articles

Thinking outside the brain: Gut microbiome influence on innate immunity within neurodegenerative disease.

Merchak A, Bolen M, Tansey M, Menees K Neurotherapeutics. 2024; 21(6):e00476.

PMID: 39482179 PMC: 11585893. DOI: 10.1016/j.neurot.2024.e00476.

Geohelminths: Use in the Treatment of Selected Human Diseases.

Szuba M, Stachera W, Piwko A, Misiak M, Rutkevich R, Sota M Pathogens. 2024; 13(8).

PMID: 39204303 PMC: 11356798. DOI: 10.3390/pathogens13080703.

Contacts with environmental biodiversity affect human health: links revealed during the initial waves of the COVID-19 pandemic.

Divin D, Toman J, Flegr J, Vinkler M Sci Rep. 2024; 14(1):17492.

PMID: 39080374 PMC: 11289463. DOI: 10.1038/s41598-024-67489-6.

Gut flora in multiple sclerosis: implications for pathogenesis and treatment.

Zhang W, Wang Y, Zhu M, Liu K, Zhang H Neural Regen Res. 2023; 19(7):1480-1488.

PMID: 38051890 PMC: 10883522. DOI: 10.4103/1673-5374.387974.

Treatment with a Lactococcus lactis that chromosomally express E. coli cfaI mitigates salivary flow loss in a Sjögren's syndrome-like disease.

Akgul A, Freguia C, Maddaloni M, Hoffman C, Voigt A, Nguyen C Sci Rep. 2023; 13(1):19489.

PMID: 37945636 PMC: 10636062. DOI: 10.1038/s41598-023-46557-3.

References

Maizels R, Pearce E, Artis D, Yazdanbakhsh M, Wynn T . Regulation of pathogenesis and immunity in helminth infections. J Exp Med. 2009; 206(10):2059-66. PMC: 2757871. DOI: 10.1084/jem.20091903. View

Zinkernagel R, Hengartner H . Regulation of the immune response by antigen. Science. 2001; 293(5528):251-3. DOI: 10.1126/science.1063005. View

Okada H, Kuhn C, Feillet H, Bach J . The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010; 160(1):1-9. PMC: 2841828. DOI: 10.1111/j.1365-2249.2010.04139.x. View

Harnett W, Harnett M . Helminth-derived immunomodulators: can understanding the worm produce the pill?. Nat Rev Immunol. 2010; 10(4):278-84. DOI: 10.1038/nri2730. View

Correale J, Farez M . Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms. J Immunol. 2009; 183(9):5999-6012. DOI: 10.4049/jimmunol.0900897. View

Van Kruiningen H, West A . Iatrogenic Trichuris suis infection. Arch Pathol Lab Med. 2007; 131(2):180. DOI: 10.5858/2007-131-180-ITSI. View

Hill D, Romanowski R, Urban Jr J . A Trichuris specific diagnostic antigen from culture fluids of Trichuris suis adult worms. Vet Parasitol. 1997; 68(1-2):91-102. DOI: 10.1016/s0304-4017(96)01055-2. View

Broadhurst M, Leung J, Kashyap V, McCune J, Mahadevan U, McKerrow J . IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med. 2010; 2(60):60ra88. DOI: 10.1126/scitranslmed.3001500. View

Santiago M, Leitao B . Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view. Eur J Intern Med. 2009; 20(8):744-8. DOI: 10.1016/j.ejim.2009.09.001. View

10.

Summers R, Elliott D, Weinstock J . Therapeutic colonization with Trichuris suis. Arch Pathol Lab Med. 2006; 130(12):1753. DOI: 10.5858/2006-130-1753b-IR. View

11.

Mancardi G, Sardanelli F, Parodi R, Melani E, Capello E, Inglese M . Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology. 1998; 50(4):1127-33. DOI: 10.1212/wnl.50.4.1127. View

12.

Gomez-Escobar N, Gregory W, Maizels R . Identification of tgh-2, a filarial nematode homolog of Caenorhabditis elegans daf-7 and human transforming growth factor beta, expressed in microfilarial and adult stages of Brugia malayi. Infect Immun. 2000; 68(11):6402-10. PMC: 97726. DOI: 10.1128/IAI.68.11.6402-6410.2000. View

13.

Rovaris M, Codella M, Moiola L, Ghezzi A, Zaffaroni M, Mancardi G . Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology. 2002; 59(9):1429-32. DOI: 10.1212/01.wnl.0000033800.93899.e1. View

14.

Feary J, Venn A, Mortimer K, Brown A, Hooi D, Falcone F . Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy. 2009; 40(2):299-306. PMC: 2814083. DOI: 10.1111/j.1365-2222.2009.03433.x. View

15.

Sormani M, Miller D, Comi G, Barkhof F, Rovaris M, Bruzzi P . Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry. 2001; 70(4):494-9. PMC: 1737302. DOI: 10.1136/jnnp.70.4.494. View

16.

Miller D, Albert P, Barkhof F, Francis G, Frank J, Hodgkinson S . Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996; 39(1):6-16. DOI: 10.1002/ana.410390104. View

17.

Costantino C, Baecher-Allan C, Hafler D . Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008; 28(6):697-706. PMC: 2752287. DOI: 10.1007/s10875-008-9236-x. View

18.

Rook G . 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: darwinian medicine and the 'hygiene' or 'old friends' hypothesis. Clin Exp Immunol. 2010; 160(1):70-9. PMC: 2841838. DOI: 10.1111/j.1365-2249.2010.04133.x. View

19.

Kradin R, Badizadegan K, Auluck P, Korzenik J, Lauwers G . Iatrogenic Trichuris suis infection in a patient with Crohn disease. Arch Pathol Lab Med. 2006; 130(5):718-20. DOI: 10.5858/2006-130-718-ITSIIA. View

20.

Summers R, Elliott D, Urban Jr J, Thompson R, Weinstock J . Trichuris suis therapy in Crohn's disease. Gut. 2004; 54(1):87-90. PMC: 1774382. DOI: 10.1136/gut.2004.041749. View